Therapeutic Use of Truncated tissue plasminogen activator (tPA)
Fibrinolytic therapy provides an alternative to mechanical reperfusion in the setting of limited medical resources for ST-segment elevation myocardial infarction (STEMI). If percutaneous coronary intervention (PCI) is not available within 120 minutes, then reteplase or other fibrinolytic therapy with recombinant human tissue plasminogen activator (tPA) should be used.
Reteplase (Retavase) is a recombinant fibrinogen activator designed for fibrinolytic therapy in acute STEMI. It can catalyze the cleavage of endogenous fibrinogen to produce fibrinolytic enzymes (plasmin), which can, in turn, degrade the fibrin matrix of thrombus, and therefore perform thrombolytic action.
Being a non-glycosylated fragment of tissue plasminogen activator (tPA), Reteplase is also called truncated tPA and consists of the kringle 2 and the protease domains of human tPA. Besides, it contains 355 of the 527 amino acids beginning with Ser1 and ending with Pro527 of the original tPA sequence, excluding the Val4 to Glu175 amino acids. Reteplase is produced through recombinant DNA technology. The target protein is expressed in Escherichia coli (E. coli) as inactive inclusion bodies that are converted to the active form by refolding and purification process. Chiesi USA (formerly EKR Therapeutics) developed Reteplase (Retavase).
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for tPA
Tissue Plasminogen Activator (tPA) Pipeline
|
Generic Name
|
Brand Name/ Alternative Name
|
Expression System
|
Indications
|
Manufacturer
|
R&D Stage
|
|
Reteplase
|
BM-06.022, Ecokinase, Rapilysin, Retavase
|
Escherichia coli
|
Acute Myocardial Infarction (AMI)
|
Chiesi USA (formerly EKR Therapeutics)
|
Approval
|
|
Reteplase, biosimilar
|
派通欣
|
Escherichia coli
|
Acute Myocardial Infarction (AMI)
|
Aide Pharma, Guizhou Yibai Pharmaceutica
|
Approval
|
|
Reteplase, biosimilar
|
瑞通立
|
Pending update
|
Acute Myocardial Infarction (AMI)
|
China Resources Angde Biotech Pharma
|
Approval
|
|
Reteplase, biosimilar
|
MiRel, R TPR 004
|
Pending update
|
Acute Myocardial Infarction (AMI)
|
Reliance Life Sciences
|
Approval
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
